anti-CCP
Selected indexed studies
- Anti-CCP biosensors in rheumatoid arthritis. (Clin Chim Acta, 2024) [PMID:38857671]
- Meta-analysis: compared with anti-CCP and rheumatoid factor, could anti-MCV be the next biomarker in the rheumatoid arthritis classification criteria? (Clin Chem Lab Med, 2019) [PMID:31141478]
- Autoantibodies in Rheumatoid Arthritis - Laboratory and Clinical Perspectives. (Front Immunol, 2021) [PMID:34054878]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Diagnostic utility and clinical relevance of anti-MCV and anti-CCP antibodies in rheumatoid arthritis. (2025) pubmed
- Meta-analysis: compared with anti-CCP and rheumatoid factor, could anti-MCV be the next biomarker in the rheumatoid arthritis classification criteria? (2019) pubmed
- Anti-CCP biosensors in rheumatoid arthritis. (2024) pubmed
- Autoantibodies in Rheumatoid Arthritis - Laboratory and Clinical Perspectives. (2021) pubmed
- The development of anticyclic citrullinated peptide (anti-CCP) antibody following severe COVID-19. (2024) pubmed
- Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease. (2022) pubmed
- Anti-CCP antibodies and bone. (2018) pubmed
- Anti CCP Antibodies in Tuberculosis. (2016) pubmed
- Strongly positive anti-CCP antibodies in patients with sacroiliitis or reactive arthritis post-E. coli infection: A mini case-series based review. (2018) pubmed
- In Contrast to Anti-CCP, MMP-Degraded and Citrullinated Vimentin (VICM) Is Both a Diagnostic and a Treatment Response Biomarker. (2022) pubmed